Effects of vitamin K
Adult
Aged
Aged, 80 and over
Antirheumatic Agents
/ administration & dosage
Arthritis, Rheumatoid
/ drug therapy
Drug Therapy, Combination
Female
Healthy Volunteers
Humans
Inhibitory Concentration 50
Leukocytes, Mononuclear
/ drug effects
Male
Methotrexate
/ administration & dosage
Middle Aged
Vitamin K 2
/ administration & dosage
Young Adult
immunosuppressive pharmacodynamics
methotrexate
peripheral blood mononuclear cells
rheumatoid arthritis
vitamin K2
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
22
03
2021
received:
21
01
2020
accepted:
25
03
2021
pubmed:
30
3
2021
medline:
4
1
2022
entrez:
29
3
2021
Statut:
ppublish
Résumé
Methotrexate (MTX) is used as anchor drug for patients with early and established rheumatoid arthritis (RA). Vitamin K Immunosuppressive pharmacodynamics of vitamin K Mitogen-activated peripheral blood mononuclear cells (PBMCs) were used to evaluate immunosuppressive pharmacodynamics of drugs in vitro. Vitamin K The above information may partially elucidate the potentiation effects of vitamin K
Sections du résumé
BACKGROUND
BACKGROUND
Methotrexate (MTX) is used as anchor drug for patients with early and established rheumatoid arthritis (RA). Vitamin K
OBJECTIVES
OBJECTIVE
Immunosuppressive pharmacodynamics of vitamin K
METHODS
METHODS
Mitogen-activated peripheral blood mononuclear cells (PBMCs) were used to evaluate immunosuppressive pharmacodynamics of drugs in vitro.
RESULTS
RESULTS
Vitamin K
CONCLUSION
CONCLUSIONS
The above information may partially elucidate the potentiation effects of vitamin K
Substances chimiques
Antirheumatic Agents
0
Vitamin K 2
11032-49-8
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
832-842Subventions
Organisme : Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan
ID : 15K08081
Organisme : State Scholarship Fund of China Scholarship Council
ID : 201808420024
Organisme : Japan China Sasakawa Medical Fellowship
ID : 2017816
Organisme : Wuhan Young and Middle-aged Medical Talent Award Plan
ID : 202055
Informations de copyright
© 2021 Société Française de Pharmacologie et de Thérapeutique.
Références
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328-2337.
Okamoto H. Vitamin K and rheumatoid arthritis. IUBMB Life. 2008;60:355-361.
Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389:2338-2348.
Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014;10:1519-1530.
Suzuki K, Tsuji S, Fukushima Y et al. Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK(2)) in postmenopausal RA patients. Mod Rheumatol. 2013;23:450-455.
Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000;15:515-521.
Okamoto H, Shidara K, Hoshi D, Kamatani N. Anti-arthritis effects of vitamin K(2) (menaquinone-4)-a new potential therapeutic strategy for rheumatoid arthritis. FEBS J. 2007;274:4588-4594.
Shishavan NG, Gargari BP, Kolahi S, Hajialilo M, Jafarabadi MA, Javadzadeh Y. Effects of vitamin K on matrix metalloproteinase-3 and rheumatoid factor in women with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. J Am Coll Nutr. 2016;35:392-398.
Shishavan NG, Gargari BP, Jafarabadi MA, Kolahi S, Haggifar S, Noroozi S. Vitamin K1 supplementation did not alter inflammatory markers and clinical status in patients with rheumatoid arthritis. Int J Vitam Nutr Res. 2018;88:251-257.
Khojah HM, Ahmed S, Abdel-Rahman MS, Alkhalil KM, Hamza AB. Vitamin K homologs as potential biomarkers for disease activity in patients with rheumatoid arthritis. J Bone Miner Metab. 2017;35:529-535.
Ebina K, Shi K, Hirao M et al. Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis. Mod Rheumatol. 2013;23:1001-1007.
Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86:301-307.
Kusano J, Tanaka S, Matsuda H et al. Vitamin K1 and Vitamin K2 immunopharmacological effects on the peripheral lymphocytes of healthy subjects and dialysis patients, as estimated by the lymphocyte immunosuppressant sensitivity test. J Clin Pharm Ther. 2018;43:895-902.
Meng K, Xu W, Miura T et al. The effects of vitamin K1 and vitamin K2 on the proliferation, cytokine production and regulatory T-cell frequency in peripheral blood mononuclear cells of paediatric atopic dermatitis patients. Exp Dermatol. 2018;27:1058-1060.
Xu W, Meng K, Wu H et al. Vitamin K2 immunosuppressive effect on pediatric patients with atopic dermatitis. Pediatr Int. 2019;61:1188-1195.
Myneni VD, Mezey E. Immunomodulatory effect of vitamin K2: implications for bone health. Oral Dis. 2018;24:67-71.
Xu W, Meng K, Kusano J et al. Immunosuppressive efficacy of tetrandrine combined with methylprednisolone against mitogen-activated peripheral blood mononuclear cells of haemodialysis patients. Clin Exp Pharmacol Physiol. 2017;44:924-931.
Xu W, Meng K, Tu Y et al. Tetrandrine potentiates the glucocorticoid pharmacodynamics via inhibiting P-glycoprotein and mitogen-activated protein kinase in mitogen-activated human peripheral blood mononuclear cells. Eur J Pharmacol. 2017;807:102-108.
Xu W, Wang X, Tu Y et al. Plant-derived alkaloid sinomenine potentiates glucocorticoid pharmacodynamics in mitogen-activated human peripheral blood mononuclear cells by regulating the translocation of glucocorticoid receptor. Phytother Res. 2019;33:187-196.
Bijlsma JW, Jacobs JW. Methotrexate: still the anchor drug in RA treatment. Joint Bone Spine. 2009;76:452-454.
Xu W, Chen S, Wang X et al. Suppressive effect of vitamin K2 against mitogen-activated peripheral blood mononuclear cells of rheumatoid arthritis patients. Int J Clin Pharmacol Ther. 2021;59:55-62.
Sumitomo S, Nagafuchi Y, Tsuchida Y et al. A gene module associated with dysregulated TCR signaling pathways in CD4(+) T cell subsets in rheumatoid arthritis. J Autoimmun. 2018;89:21-29.
Waldmann TA. The interleukin-2 receptor. J Biol Chem. 1991;266:2681-2684.
Kondo Y, Yokosawa M, Kaneko S et al. Transcriptional regulation of CD4+ T cell differentiation in experimentally induced arthritis and rheumatoid arthritis. Arthritis Rheumatol. 2018;70:653-661.
Benedetti G, Miossec P. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol. 2014;44:339-347.
Kotake S, Udagawa N, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103:1345-1352.
Kotake S, Nanke Y, Mogi M et al. IFN-g-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol. 2005;35:3353-3363.
McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis - shaping the immunological landscape. Nat Rev Rheumatol. 2016;12:63-68.
Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-α: induction of TNF receptors on human T cells and TNF-α-mediated enhancement of T cell responses. J Immunol. 1987;138:1786-1790.
Siegel JP. Effects of interferon-l on the activation of human T lymphocytes. Cell Immunol. 1988;111:461-472.